Logo image
Back
Current Guidelines on Antiplatelet Agents for Secondary Prevention of Noncardiogenic Stroke: An Evidence-Based Review
Journal article   Peer reviewed

Current Guidelines on Antiplatelet Agents for Secondary Prevention of Noncardiogenic Stroke: An Evidence-Based Review

B. Brent Simmons, Albert Yeo, Kent Fung and American Stroke Association
Postgraduate medicine, v 122(2), pp 49-53
01 Mar 2010
DOI: https://doi.org/10.3810/pgm.2010.03.2121
PMID: 20203455
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

General & Internal Medicine Life Sciences & Biomedicine Medicine, General & Internal Science & Technology
Antiplatelet therapy is a mainstay of secondary prevention of ischemic strokes. Recent studies, such as Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS), the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial, and the European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), have added much to our understanding about how best to utilize the various antiplatelet agents available. Aspirin has been shown to reduce the risk of recurrent strokes, and the combination of aspirin and dipyridamole has repeatedly been shown to outperform aspirin alone. Recently, clopidogrel was demonstrated to be "noninferior" to an aspirin/dipyridamole combination, and can be considered as a first-line agent. The American Stroke Association and American Heart Association have clear recommendations on how to utilize these agents.

Metrics

10 Record Views
10 citations in Web of Science
9 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Medicine, General & Internal
Logo image